Member Biography
Dr. Anne Winkler, M.D., Ph.D, received her medical degree from the University of Missouri-Columbia, where she also completed her residency in Internal Medicine and her Fellowship in Rheumatology. She completed her PhD in Microbiology at the University of Missouri-Columbia as well. She has practiced Rheumatology in the Springfield area since 1989.
She has published over 15 papers in the area of Rheumatology, and continues to serve as principle investigator in clinical research trials. Dr. Winkler has won the 417 Magazine Best Doctor in Rheumatology in 2009, 2008, 2006, 2005, 2003 and 2002. She has also served as Governor of the American College of Physicians (ACP). Dr. Winkler was awarded mastership in the ACP in 2008.
PhD: PhD, Microbiology
University of Missouri
Columbia, Missouri
1985 – 1989
MD: Doctor of Medicine
University of Missouri
Columbia, Missouri
1977 – 1981
BA: Bachelor of Arts
University of Pennsylvania
1971 – 1974
Residency: Resident, Internal Medicine
University of Missouri
Columbia, Missouri
1981 – 1984
Fellowship: Fellow, Division of Immunology/Rheumatology
University of Missouri
Columbia, MO
2007 – Voted Springfield’s Best Rheumatologist
2005 – Voted Springfield’s Best Rheumatologist
2003 – Voted Springfield’s Best Rheumatologist
2003 – Woman of the Year, Springfield Business Journal
2002 – Voted Springfield’s Best Rheumatologist
2002 – Lifetime Member of Who’s Who
1996 – Who’s Who of American Women
1995 – International Who’s Who of Professionals
1994 – Fellow, American College of Physicians
1991 – Who’s Who in Medicine
1987 – 1989 – Arthritis Foundation Postdoctoral Fellow Grant
1986 – Diplomate, Subspecialty – Rheumatology, American Board of Internal Medicine
1984 – Diplomate, American Board of Internal Medicine
1981 – Licensure, State of Missouri
1974 – Phi Beta Kappa
1974 – Magna cum laude, University of Pennsylvania
1972, 1973, 1974 – Academic Distinction, University of Pennsylvania
1971 – National Merit Finalist
Professional Organizations
- American Medical Women’s Association, 1980 – present
- American College of Physicians, 1989 – present
- Association for the Advancement of Science, 1984 – present
- American College of Rheumatology, 1989 – present
- Southwest Regional Arthritis Center at St. John’s Regional Health Center, 1989 – present
- Missouri Juvenile Arthritis Task Force, 1991 – 1992
- Missouri Arthritis Advisory Board, 1990 – present
- St. John’s Medical Research Institute Board, 2007 – present
- The Summit Preparatory School Board 2004 – present
Committees and Volunteer Work
- 2007 – present: Member, St. John’s Medical Research Institute Board
- 2005 – 2007: Leader, Midwest Rheumatology Association, Ozark Branch
- 2004 – present: Chair, The Summit Preparatory School Board of Trustees
- 2003 – 2007: Governor, ACP
- 2002 – 2005: Leader, Women Physicians Group
- 2002 – 2003: Governor – Elect, ACP
- 1999 – 2002: Council Member, Missouri ACP
- 1998 –2000: Chair, Physician Manpower Committee
- 1998 – present: Medical Editor, Southwest Missouri Regional Arthritis Center Newsletter
- 1998 – present: Medical Director, Fibromyalgia Support Services, St. John’s Hammons Heart Institute
- 1996 – present: Activities Committee, Missouri ACP
- 1994 – present: Medical Advisor, Fibromyalgia Support Group
- 1993 – 1994: Chair, Department of Medicine Subspecialties
- 1990 – present: Medical Director, Ozark Lupus Group
- 1990 – present: Women Physicians’ Committee, Missouri ACP
- 1989 – present: Assistant Medical Director, Southwest Missouri Regional Arthritis Center
Publications
- Winkler, A. and D. Wilson: Thyroid acropachy: case report and review of the literature.
1985. Missouri Med 82:756-780. - Winkler A., Finan, M., Pressly T. and R. Roberts: CMV retinitis in rheumatologic disease.
1987. Arthritis and Rheum 30:106-108. - Pressly, T., Scott W., Ide, C., Winkler, A. and G. Reams: Ocular complications of Tangier’s
disease. 1987. Amer J Med 83:991-994. - Smith, H.L., Pressly, T., Watts, C., Winkler, A. and J. Bryan: Neurosarcoid presenting as ataxia
with CT and MRI findings: case report and discussion. 1987. Clin Neuroscience 1:10-11. - Winkler, A., McKown, R. and K.S. Wise: Monoclonal autoantibody recognizing a unique
subset of snRNP complexes. 1988 J. Immunol 140:69-77. - Winkler, A., Jackson, R., Kay, D., Mitchell, E., Carmiagnini, S. and G. Sharp: Successful
treatment of SLE-associated aplastic anemia. 1988. Arthritis and Rheum 41:643-644. - Winkler, A., Pressly, T. and D. Wilson: Androgen deficient osteoporosis. 1988. Missouri
Med 85:84-86. - Winkler, A., Pressly, T., Alpert, M., Jackson, R., Mukerji, V. and G. Sharp: Value and
limitation of calcium channel blockade in patients with pulmonary arterial hypertension
associated with CREST. 1988. Angiology 39:385-389. - Pressly, T., Treadwell, E., Ansbacher, L., Winkler, A. and S. Walker: Eosinophilic fascitis,
porphyria cutanea tarda and granulocytopenia in a patient with inflammatory arthritis. 1989.
J. Rheum. - Winkler, A., Kreivi, J.P., Akusjarvi, G. and K.S. Wise: Monoclonal autoantibody recognizes
higher order snRNP complex involved in splicing. Submitted. - Takeda, Y., Nyman, N., Winkler, A., Wise, K.S., Hoch, S.O., Pettersson, I., Anderson, S.K.,
Wang, R.J., Wang, G.S. and G.C. Sharp: Epitope mapping of the UI snRNP – associated
70K polypeptide. 1990. Clin Immunol Immunopath. - Anderson, Frances and A Winkler: Benefits of Long-Term Fibromyalgia Treatment with
Multi-disciplinary Program. J Musculoskeletal Diseases, Dec 2006. - Kurland, Winkler and Coyle: Prevalence of Irritable Bowel Syndrome and Deression in
Fibromyalgia. Digestive Disease and Science. 51 (3) 454-460. - Anderson, Frances and A Winkler. Group Therapy in Fibromyalgia. In Press: J
Musculoskeletal Diseases.
Presentations / Abstracts
- Winkler, A., McKown, R. and K.S. Wise: Novel monoclonal autoantibody specificity associated
with ribonucleoprotein complexes. 1986. Fed Proceedings 45:492 (Abstract 1968). - Pressly, T., Winkler, A. and D. Wilson: Male osteoporosis: 2 unusual cases. 1987. Southern
Medical Association, 81st
Annual Scientific Assembly. - Pressly, T., Winkler, A., Alpert, M., Mukerji, V. and G. Sharp: Value and limitations of calcium
channel blockade in patients with pulmonary arterial hypertension associated with the Crest
syndrome. 1987. American College of Angiology , 34th Annual Meeting. - Winkler, A., McKown, R. and K.S. Wise: Monoclonal autoantibody which recognizes a unique
subset of snRNP. Mol Biol Reports 12:164. - Pettersson, I., Nyman, U., Winkler, A., Wise, K.S. and N. Ringertz: Colocalization studies of
different sets of snRNP using monoclonal autoantibodies. 1987. EMBO Eukaryotic RNP
Meeting. - Winkler, A., McKown, R. and K.S. Wise: Monoclonal autoantibody recognizing higher order
snRNP complexes. 1987. Arthritis Foundation Fellows Conference. - Takeda, Y., Nyman, N., Winkler, A., Wise, K.S., Hoch, S.O., Pettersson, I., Anderson, S.K.,
Wang, R.J., Wang, G.S. and G.C. Sharp: Epitope mapping of the UI snRNP – associated 70K
polypeptide. 1990. Arthritis Rheum 32:S26.
Research Protocols
- “A Randomized, Double-Blind, Parallel Group, International Study To Evaluate The
Safety And Efficacy Of Ocrelizumab Compared To Placebo In Patients With Active
Rheumatoid Arthritis Who Have An Inadequate Response To At Least One AntiTNF-
Therapy.” Roche & Genentech, Principal Investigator. - “A Phase 2, Randomized, Double-Blind, Placebo controlled, Parallel-Group Study of CP195543
and Celecoxib Dual Therapy in the Treatment of the Signs and Symptoms of Rheumatoid Arthritis in Subjects who are Inadequately Controlled on Methotrexate”, Pfizer,
Principal Investigator - “A Randomized, Double Blind, Parallel-group Study of Cardiovascular Safety in
Osteoarthritis or Rheumatoid Arthritis Patients with or at High Risk for Cardiovascular
Disease comparing Celecoxib with Naproxen and Ibupofen”, Pfizer, Principal Investigator - “Long-term extension study of safety during treatment with tocilizumab (MRA) in patients
completing treatment in MRA core studies”, Hoffman-La Roche, Ltd, Principal Investigator - “A randomized, double-blind, placebo-controlled, parallel group study of the safety and
reduction of signs and symptoms during treatment with MRA versus placebo, in combination
with traditional DMARD therapy in patients with moderate to severe active rheumatoid
arthritis and an inadequate response to current DMARD therapy”, Hoffmann-La Roche Ltd,
Principal Investigator - “A 39-Week, Open-Label, Extension, A 13-Week, Multicenter, Randomized, Double-Blind,
Double-Dummy, Placebo-Controlled, Parallel Trial of 2 Different Dose Regimens of
Lumiracoxib (100 mg od and 200 mg od initial dose for two weeks followed by 100 mg od)
in Patients with Primary Knee Osteoarthritis, Using Celecoxib (200 mg od) as a Comparator”,
Novartis Pharmaceuticals, Principal Investigator - “A Multi-Center Open-Label Study to Assess the Durability and Safety of the Prevention of
Bone Loss by Treatment with GL701 (Prestara™) in Women with Systemic Lupus
Erythematosus Receiving Treatment with Glucocorticoids”, Genelabs Technologies,
Principal Investigator - “A Double-Blind, Placebo Controlled Study of the Efficacy and Tolerability of Once Daily
Celebrex® (celecoxib) vs. Placebo in the Treatment of Subjects with Osteoarthritis of the
Knee Non-Responsive to Naproxen and Ibuprofen”, Pfizer, Principal Investigator - “A Randomized, Double-Blind, Multi-Center, Placebo Controlled Study to Assess Prevention
of Bone Loss by Treatment with GL701 (Prestara™) in Women with Systemic Lupus
Erythematosus Receiving Treatment with Glucocorticoids”, Genelabs Technologies, Inc.,
Principal Investigator - “A 13-Week, Multicenter, Randomized, Double-Blind, Double-Dummy, Placebo-Controlled,
Parallel Trial of 2 Different Dose Regiments of Lumiracoxib (100 mg od and 200 mg od
initial dose for two weeks followed by 100 mg od) in Patients with Primary Knee
Osteoarthritis, using Celecoxib (200 mg od) as a Comparator”, Novartis Pharmaceuticals
Corporation, Principal Investigator - “A Phase III, Randomized, Multicenter, Allopurinol and Placebo-Controlled Study Assessing
the Safety and Efficacy of Oral Febuxostat in Subjects with Gout”, TAP Pharmaceuticals,
Principal Investigator - ” Multinational, multicenter, double-blind, randomized, placebo controlled, parallel group
study assessing the efficacy of intravenous zoledornic acid in preventing subsequent
osteoporotic fractures after a hip fracture”, Novartis Pharmaceuticals Corporation,
Subinvestigator - “An 18-Month Open Label Extension Study (OLES) of the Safety and Efficacy of
Recombinant Human Parathyroid Hormone, rhPTH(1-84), ALX1-11, in Women with
Postmenopausal Osteoporosis Who Participated in Protocol ALX1-11-93001”, NPS Allelix,
Subinvestigator - “Raloxifene Alendronate Comparison In Postmenopausal Women With Osteoporosis”, Eli
Lilly, Subinvestigator - “A Multicenter, Double-Blind, Randomized Study to Evaluate the Efficacy and Safety of
Combination Treatment with Anakinra (IL-1ra) and PEGylated Recombinant Methionyl
Human Soluble Tumor Necrosis Factor Receptor Type I (PEGsTNF-RI) in Subjects with
Rheumatoid Arthritis Receiving Methotrexate”, Amgen, Inc., Principal Investigator - “A Randomized, Double-Blind, Double-Dummy, Parallel-Group, Multicenter Study to
Evaluate and Compare the Effects of Alendronate and Raloxifene on Bone Mineral Density
in Postmenopausal Women with Osteoporosis. (EFFECT Study-Efficacy of Fosamax vs.
Evista Comparison Trial)”, Merck & Co., Inc., Subinvestigator - “An 18-Month Double-Blind, Placebo-Controlled, Phase III, Trial with a 12-Month Interim
Analysis of the Effect of Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture
Incidence in Women with Postmenopausal Osteoporosis”, NPS Allelix, Subinvestigator - “A Twelve-Week, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Study of
Oral Alendronate Sodium (70 mg Once Weekly) in Patients with Osteoporosis”, Merck &
Co., Subinvestigator - “A Randomized, Placebo-Controlled, Parallel Group, Double Blind Study to Evaluate the
Safety and Efficacy of Rofecoxib and Celecoxib in Patients with Osteoarthritis of the Knee or
Hip”, Merck & Co., Inc., Principal Investigator - “A Randomized, Double Blind, Multi-Center Study to Evaluate the Tolerability and
Effectiveness of Rofecoxib (VIOXX®) 25mg q.d. Vs. Naproxen 500 mg b.i.d. in Patients with
Osteoarthritis” Merck & Co., Inc., Principal Investigator
Dr. Anne Winkler
Rheumatologist
Facilities Served
Conditions Treated
- Arthritis
- Rheumatism
- Autoimmune diseases
- Low back pain
- Osteoporosis